Abstract:FHIT (fragile histidine triad gene), a candidate tumor suppressor gene, was recently identified and cloned at chromosome 3p14.2. Alterations of this gene have been reported in a number of primary human tumors, including colorectal, esophageal, gastric and lung carcinomas. However, some reports have found no abnormalities in this gene. We investigated a total of 63 primary esophageal tumors, nine esophageal cancer cell lines and 17 ulcerative colitis-associated neoplasms (UCANs) for alterations of FHIT. In 13 esophageal tumors, we employed overlapping reverse transcriptase-PCRs (RT – PCRs) to amplify and sequence the complete open reading frame of FHIT. One of 13 primary esophageal tumors analysed by RT – PCR expressed no detectable FHIT transcript; the remaining 12 expressed normal-sized transcripts with wild-type open reading frame sequences. In an additional 50 esophageal tumors, the polymorphic microsatellite loci D3S1300 and D3S1313 were used to evaluate loss of heterozygosity (LOH) at 3p14.2. Eleven of these 50 tumors showed LOH at one or both loci. In all these 11 tumors, genomic PCR and direct sequencing of FHIT exons 5 – 9 was performed. This analysis revealed that none of these 11 primary esophageal tumors contained any alterations in the FHIT open reading frame or adjacent intron sequences. Finally, among 17 UCANs, the in vitro synthesized protein (IVSP) assay detected no truncated protein products, nor were there any abnormalities in size or DNA sequence of FHIT RT – PCR products. However, in six of nine esophageal carcinoma cell lines, no FHIT RT-PCR product was detectable using either of the overlapping primer sets. Genomic PCR and direct sequencing of exons 5 – 9, also performed in these nine cell lines, revealed wild-type sequence in eight cell lines; however, one cell line contained no exon 5 PCR product. This cell line also lacked detectable FHIT transcript. These data suggest that the open reading frame of FHIT is not important in the development or progression of most primary esophageal carcinomas or UCANs, although lack of expression of the FHIT transcript may be common in esophageal cancer-derived cell lines. The possibility of an additional tumor suppressor gene at chromosome 3p14.2 remains to be evaluated.

Study on Association of Fragile Histidine Triad Gene Transcripts with Human Gastric Cancer

Expressions of FATI0 and P53 Mutant in Human Gastric Cancer and Their Relations

The relationship between FAT10 mRNA expression and feature of clinical pathology in gastric carcinoma

FAT10 Level in Human Gastric Cancer and Its Relation with Mutant P53 Level, Lymph Node Metastasis and TNM Staging.

Homozygous Deletion and Mutation of Antioncogene FHIT Gene Exon 5 and Exon 8 in Gastric Carcinoma

Effect of Fragile Histidine Triad Gene on Apoptosis of MGC-803 Gastric Cancer Cells

Expression of FHIT Gene in Gastric Cancer and Relationship with Proliferation of Tumor Cell

Expression of Trefoil Factors 1 and 2 in Precancerous Condition and Gastric Cancer

Association between H-RAS T81C genetic polymorphism and gastrointestinal cancer risk: A population based case-control study in China

Study on relationship between mutant p53 and multidrug resistance gene 1 in gastric cancer

Relationship between forkhead box P3 gene polymorphisms and susceptibility to gastric cancer

FHIT gene alterations in esophageal cancer and ulcerative colitis (UC)

[Allelic Loss and Down-Regulation of FHIT Gene Expression in Esophageal Squamous Cell Carcinoma].

Expression of FHIT Protein in Primary Carcinoma of the Gallbladder and Its Significance.

Telomerase Activity and hTRT Gene Expression in Gastric Cancer

The Expression of FHIT Protein in Progression of Breast Carcinoma

Clinicopathological Significance of Expression of Fragile Histidine Triad Protein in Neuroendocrine Lung Carcinoma

Research Progress on Relationship among Microsatellite Instability, HMLH1, FHIT Gene and Gastric Carcinoma

[Alteration of P73 and P51 Genes and Its Significance in Human Gastric Carcinogenesis]

Study of mRNA Expressions of FHIT Genes in Patients with Non- small Cell Lung Cancer

Integrated analysis of FHIT gene alterations in cancer